<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164056</url>
  </required_header>
  <id_info>
    <org_study_id>2019-192</org_study_id>
    <nct_id>NCT04164056</nct_id>
  </id_info>
  <brief_title>Hippocampal and Thalamic DBS for Bilateral Temporal Lobe Epilepsy</brief_title>
  <official_title>Hippocampal and Thalamic Deep Brain Stimulation for Bilateral Temporal Lobe Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare the safety and effectiveness of deep brain stimulation of the
      hippocampus and the anterior nucleus of the thalamus for reducing the frequency of seizures
      in patients with bilateral temporal lobe epilepsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The outcome of resective surgery for bilateral temporal lobe epilepsy (BTLE) is poor.
      Neuromodulation such as deep brain stimulation is an alternative therapy for patients with
      drug-resistant epilepsy, especially for those not suitable for resective surgery. This
      prospective, randomized, open-label trial aims to compare the effectiveness of deep brain
      stimulation of the hippocampus and the anterior nucleus of the thalamus for bilateral
      temporal lobe epilepsy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>3 years after DBS</time_frame>
    <description>The rate of patients response to DBS, patients have at least 50% decrease in average seizure frequency after DBS are considered as responder.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure-Free Rate</measure>
    <time_frame>3 years after DBS</time_frame>
    <description>The rate of patients who achieve seizure free after DBS. Patients don't have seizure for at least 1 year are considered seizure free.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Seizure Frequency</measure>
    <time_frame>3 years after DBS</time_frame>
    <description>The seizure frequency after DBS compared to the seizure frequency in baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Seizure-free Days</measure>
    <time_frame>1 year and 3 years after DBS</time_frame>
    <description>The percentage of seizure-free days after DBS compared to the percentage of seizure-free days in baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Maximum Length of Seizure Intervals</measure>
    <time_frame>1 year and 3 years after DBS</time_frame>
    <description>The maximum length of seizure intervals after DBS compared to the maximum length of seizure intervals in baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GTCS Frequency</measure>
    <time_frame>1 year and 3 years after DBS</time_frame>
    <description>The GTCS frequency after DBS compared to the GTCS frequency in baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Sudden Unexplained Death in Epilepsy (SUDEP)</measure>
    <time_frame>1 year and 3 years after DBS</time_frame>
    <description>The Incidence Rate after DBS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Memory</measure>
    <time_frame>1 year and 3 years after DBS</time_frame>
    <description>The memory test scores after DBS compared to baseline. Wechsler memory scale (WMS, ≤51 ~ 150, higher scores mean better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Function</measure>
    <time_frame>1 year and 3 years after DBS</time_frame>
    <description>The cognitive test scores after DBS compared to baseline. Montreal Cognitive Assessment(MoCA, 0-30 scores, higher scores mean better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression</measure>
    <time_frame>1 year and 3 years after DBS</time_frame>
    <description>The depression test scores after DBS compared to baseline. Hamilton depression scale (HAMD, 0-64 scores, lower scores mean better outcome)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events Rate</measure>
    <time_frame>1 year and 3 years after DBS</time_frame>
    <description>The rate of adverse events related to the implantation surgery or DBS devices.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Epilepsy, Temporal Lobe</condition>
  <arm_group>
    <arm_group_label>stimulation on the hippocampus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>deep brain stimulation on the hippocampus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stimulation on the anterior nucleus of the thalamus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>deep brain stimulation on the anterior nucleus of the thalamus</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>deep brain stimulation</intervention_name>
    <description>deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus</description>
    <arm_group_label>stimulation on the anterior nucleus of the thalamus</arm_group_label>
    <arm_group_label>stimulation on the hippocampus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients between 12 to 60 years old.

          2. Bilateral temporal lobe epilepsy patients proved by VEEG or SEEG.

          3. At least 3 seizures per month but not more than 10 seizures per month, and the longest
             seizure interval is no more than 30 days during the baseline.

          4. Patients failed to at least 3 antiepileptic drugs (AEDs), and are receiving at least 1
             AEDs now.

          5. Be able to complete seizure diary.

          6. Agree to participate this study and sign informed consent.

        Exclusion Criteria:

          1. Extratemporal lobe epilepsy or with potential extratemporal epileptogenic focus.

          2. Patients with psychogenic non-epileptic seizures.

          3. IQ &lt; 70, or unable to complete the study.

          4. Patients are pregnant or plan for it.

          5. Patients with implanted electrical stimulation medical device.

          6. Patients with other severe neuropsychiatric disorders such as dementia, schizophrenia,
             or neurodegenerative diseases.

          7. Patients with cerebral lesions which unsuitable for lead implantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuang Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Epilepsy Center, Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuang Wang, MD</last_name>
    <phone>+86 0571-87767120</phone>
    <email>wangs77@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuang Wang, MD</last_name>
      <phone>+86 0571-87767120</phone>
      <email>wangs77@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Fisher R, Salanova V, Witt T, Worth R, Henry T, Gross R, Oommen K, Osorio I, Nazzaro J, Labar D, Kaplitt M, Sperling M, Sandok E, Neal J, Handforth A, Stern J, DeSalles A, Chung S, Shetter A, Bergen D, Bakay R, Henderson J, French J, Baltuch G, Rosenfeld W, Youkilis A, Marks W, Garcia P, Barbaro N, Fountain N, Bazil C, Goodman R, McKhann G, Babu Krishnamurthy K, Papavassiliou S, Epstein C, Pollard J, Tonder L, Grebin J, Coffey R, Graves N; SANTE Study Group. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010 May;51(5):899-908. doi: 10.1111/j.1528-1167.2010.02536.x. Epub 2010 Mar 17.</citation>
    <PMID>20331461</PMID>
  </results_reference>
  <results_reference>
    <citation>Salanova V, Witt T, Worth R, Henry TR, Gross RE, Nazzaro JM, Labar D, Sperling MR, Sharan A, Sandok E, Handforth A, Stern JM, Chung S, Henderson JM, French J, Baltuch G, Rosenfeld WE, Garcia P, Barbaro NM, Fountain NB, Elias WJ, Goodman RR, Pollard JR, Tröster AI, Irwin CP, Lambrecht K, Graves N, Fisher R; SANTE Study Group. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology. 2015 Mar 10;84(10):1017-25. doi: 10.1212/WNL.0000000000001334. Epub 2015 Feb 6.</citation>
    <PMID>25663221</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Temporal Lobe</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

